All Outputs (4)

Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia (2020)
Journal Article
Davis, L., Mills, K. I., Orchard, K. H., & Guinn, B. A. (2020). Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. Cancers, 12(10), 1-22. https://doi.org/10.3390/cancers12102769

Few studies have compared gene expression in paediatric and adult acute myeloid leukaemia (AML). In this study, we have analysed mRNA-sequencing data from two publicly accessible databases: (1) National Cancer Institute's Therapeutically Applicable R... Read More about Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia.

Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., Mills, K. I., Orchard, K., & Guinn, B. (2020). Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.

Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., Mills, K. I., Orchard, K., & Guinn, B. (2020). Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80% of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia.

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Freire Boullosa, L., Van Tendeloo, V., Smits, E., Mills, K. I., Orchard, K. H., & Guinn, B. A. (2020). New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 69(5), 867-877. https://doi.org/10.1007/s00262-020-02484-0

Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associat... Read More about New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.